Proceeds from the financing are set to go toward expanding its capacity and investing in technologies designed to complement and extend its proprietary antibody discovery engine, as well as toward expanding its staff and facilities . . .
Home Antibodies Antibody Drug Conjugates AbCellera’s CEO: Flattening the Curve of Technology Development
- Antibodies
- Antibody Drug Conjugates
- Drug Discovery
- Bispecific Antibodies
- Epitope Mapping
- Monoclonal Antibodies
- GEN Edge
- Financing
AbCellera’s CEO: Flattening the Curve of Technology Development
Antibody Discovery Company Looking beyond COVID-19 with Eli Lilly; Expanding Technologies, Staff, and Facilities with $105M Series B Financing
An AbCellera scientist prepares reagents for a microfluidicsingle-cell assay. The company plans to expand its capacity, invest in technologies designed to complement and extend its proprietary antibody discovery engine, as well as expand its staff, and facilities through its just-completed $105 million in Series B financing. [AbCellera]
![Dual-mechanism oral small molecule MBX-2982 acts as GPR119 agonist. [© Celso Pupo - Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/June25_2010_2776985_DiabetesParaphernalia_SanofiAventisMetabolexDiabetesCollab_Crop2031951925-2-80x60.jpg "Type 2 Diabetes Risk Linked to Prolonged Use of Common Acid Reflux Drugs")
